Nolvadex (Tamoxifen Citrate)

Tamoxifen citrate acts as a selective estrogen receptor modulator. It binds competitively to estrogen receptors in breast tissue, blocking estrogen‑driven signaling that promotes tumor cell growth, while its metabolites retain higher affinity for the receptor, enhancing the anti‑estrogenic effect.

The dosage of Nolvadex is individualized by the prescribing clinician based on the specific indication, patient characteristics, and treatment protocol. Dosing regimens are established by oncologists or qualified healthcare professionals and should not be altered without medical guidance.

Tamoxifen citrate is generally contraindicated in pregnancy because it may cause fetal harm. Women of child‑bearing potential should use effective contraception during treatment and for a period after discontinuation. Safety during breastfeeding has not been established, and breastfeeding is usually discouraged.

To request Nolvadex, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nolvadex belongs to the selective estrogen receptor modulator class, differing from aromatase inhibitors and pure anti‑estrogens. While aromatase inhibitors lower systemic estrogen levels, tamoxifen blocks estrogen receptors directly in breast tissue, offering an alternative mechanism that may be preferred in pre‑menopausal patients or specific clinical scenarios.

Nolvadex should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in areas with high humidity or temperature fluctuations.

Nolvadex is taken orally, usually as a tablet, with or without food as directed by the prescriber. Patients should swallow the tablet whole with a glass of water and follow the dosing schedule provided by their healthcare professional.

Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, the development of endometrial cancer, significant liver function abnormalities, and rare severe allergic reactions. Patients should be monitored regularly for signs of these conditions and report any concerning symptoms promptly.

Nolvadex is contraindicated in individuals with a known hypersensitivity to tamoxifen or any of its excipients, in pregnant women, and in patients with a history of thromboembolic disorders unless the benefits outweigh the risks. Clinicians should also avoid use in patients receiving estrogen‑containing therapies without careful assessment.